Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort

BACKGROUND AND OBJECTIVE: Benralizumab (Fasenra(™)) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β(2)-agonists. We aimed to identify and describe the...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubier, Michel, Thabut, Gabriel, Fabry-Vendrand, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124449/
https://www.ncbi.nlm.nih.gov/pubmed/30214249
http://dx.doi.org/10.2147/JAA.S170866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124449/
https://www.ncbi.nlm.nih.gov/pubmed/30214249
http://dx.doi.org/10.2147/JAA.S170866

Ejemplares similares